MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate — Hagens Berman
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate — Hagens Berman MLTX Investors with Losses Encouraged to Contact the Firm GlobeNewswire November 12, 2025 SAN FRANCISCO, Nov. 12, 2025 (GLOBE NEWSWIRE) — A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. […]